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Mucorales have been increasingly reported as cause of invasive fungal infections in immunocompromised subjects, particularly
in patients with haematological malignancies or uncontrolled diabetes mellitus and in those under deferoxamine treatment or
undergoing dialysis. The disease often leads to a fatal outcome, but the pathogenesis of the infection is still poorly understood
as well as the role of specific virulence determinants and the interaction with the host immune system. Members of the order
Mucorales are responsible of almost all cases of invasive mucormycoses, the majority of the etiological agents belonging to the
Mucoraceae family. Mucorales are able to produce various proteins and metabolic products toxic to animals and humans, but the
pathogenic role of these potential virulence factors is unknown. The availability of free iron in plasma and tissues is believed to be
crucial for the pathogenesis of these mycoses. Vascular invasion and neurotropism are considered common pathogenic features of
invasive mucormycoses.
1. Introduction
The Mucorales, which is the core group of the traditional
Zygomycota [1–3], have been recently reclassified into the
subphylum Mucoromycotina of the Glomeromycota phylum
of the kingdom Fungi [4]. This new classification does
not include Zygomycota, because the authors consider
the phylum polyphyletic, indeed the name zygomycosis,
which encompassed infections caused by members of
Mucorales and Entomophthorales, has become obsolete [4].
The Mucorales are characterized by aseptate (coenocytic)
hyaline hyphae, sexual reproduction with the formation
of zygospores, and asexual reproduction with nonmotile
sporangiospores. They are ubiquitous in nature, being found
in food, vegetation, and soil [1–3]. The majority of the
invasive diseases are caused by genera of the Mucoraceae
family, and the resulted disease is called mucormycosis [1–
3, 5–7]. Transmission occurs by inhalation of aerosolized
spores, ingestion of contaminated foodstuﬀs, or through
cutaneous exposure, the latter being the most important
mode of acquisition of mucormycosis in immunocompetent
hosts [6, 8]. Risk factors for invasive diseases include uncon-
trolled diabetes mellitus, haematological malignancies, bone
marrow and solid organ transplantation, deferoxamine ther-
apy, corticosteroid therapy, or other underlying conditions
impairing the immune system [9]. Limited activity of some
principal classes of antifungal drugs (i.e., echinocandins
and azole derivatives) as well as vascular invasion and
neurotropic activity could explain the high mortality seen
in mucormycosis [9, 10]. This paper, together with others
published in this special issue, reviews the clinical spectrum
of and risk factors for mucormycosis with particular empha-
sis on the role of fungal traits interacting with human host
defences.
2. Epidemiology
A few members of the Mucorales (Table 1) are able to
grow in human tissues causing a wide spectrum of clinical
diseases. The entity and severity of the disease depends on
the interaction between the fungus and the host immune
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Table 1: Agentsa of mucormycosis belonging to Mucorales order of the Glomeromycota phylum.
Order Family Genus Species Maximum growth temp (◦C)
Mucorales Mucoraceae Rhizopus oryzae >37◦C
microsporus >37◦C
azygosporus >37◦C
schipperae >37◦C
Mucor circinelloides >37◦C
indicus >37◦C
racemosus 32◦C
ramosissimus 36◦C
Rhizomucor pusillus >37◦C
Lichteimia corymbifera >37◦C
(Absidia)
Apophysomyces elegans >37◦C
Cunninghamellaceae Cunninghamella bertholletiae >37◦C
Saksenaeaceae Saksenaea vasiformis >37◦C
Syncephalastraceae Syncephalastrum racemosum >37◦C
defences [5, 7, 11]. In their exhaustive review, Roden and
coworkers analysed 929 cases of documented infections
caused by members of the former Zygomycota since 1885 [9].
They found that 19% of patients did not have any underlying
disease at time of infection, while diabetes (36% of cases)
was the main risk factor for developing the infection among
patients with underlying conditions [9]. More recently,
230 cases of infections were collected in 13 European
countries between 2005 and 2007 [12]. The majority of
patients (53%) had haematological malignancies (44%) and
haematopoietic stem-cell transplantation (9%) as underlying
conditions, while only 9% of patients presented diabetes
mellitus as the main risk factor [12]. Rhizopus spp. are the
most common causative agents of invasive mucormycosis,
Mucor spp. and Lichteimia (formerly Absidia) spp. rank as
second and/or third cause [6–9]. Although mucormycosis
remains a highly fatal disease, its burden is still low, as
well documented by Pagano and coworkers [13]. They were
able to demonstrate that mucormycosis aﬀected about 0.1%
of 11,802 patients with hematologic malignancies. Among
the 346 cases of proven and probable mold infections, only
14 (4%) were caused by members of Mucorales [13]. In
immune-competent subjects, mucormycosis generally devel-
ops as a consequence of traumatic injuries, and the disease
commonly involves skin even if possible dissemination from
skin to contiguous organs can occur [9, 11].
3. The Infection
Mucormycosis can be classified in rhinocerebral, pulmonary
and disseminated, abdominal-pelvic and gastric, and cuta-
neous or chronic subcutaneous diseases. Common features
of rhinocerebral, pulmonary, and disseminated diseases
include blood vessel invasion, hemorrhagic necrosis, throm-
bosis, and a rapid fatal outcome.
Rhinocerebral mucormycosis is more often associated
with uncontrolled diabetes mellitus and ketoacidosis than
malignancies or deferoxamine therapy. Inhaled spores col-
onize at first the upper turbinates and paranasal sinuses
and cause sinusitis. Depending on the underlying disease,
the fungus can rapidly invade the central nervous system,
causing symptoms like an altered mental state, progression
to coma, and death within a few days [1–3, 5–11].
Pulmonary mucormycosis is commonly seen in patients
with leukemia, lymphoma, solid organ or bone marrow
transplantation, and diabetes but is occasionally reported
also in apparently healthy subjects. Disease manifestations
vary from a localized nodular lesion to cavitary lesions
and dissemination; in the latter case, massive hemoptysis
generally occurs. Crude mortality is lower (60%) in cases
of isolated lesions than in severe pulmonary (87%) and
disseminated (95%) diseases [9].
Gastrointestinal disease is a rare manifestation of
mucormycosis, and it is mainly associated with malnutrition
in presence of predisposing factors, especially in children
with amoebic colitis, typhoid, and pellagra [11]. In the most
severe cases, the disease can be characterized by ulceration
of the mucosa and invasion of blood vessels with subsequent
production of necrotic ulcers, this form of the disease is fatal
[3, 11].
Cutaneous mucormycosis may be a primary disease
following skin barrier break or may occur as a consequence
of hematogenous dissemination from other sites, and the
outcome of the disease is strictly dependent on the patients’
conditions. Primary cutaneous mucormycosis can involve
the subcutaneous tissue as well as the fat, muscle and fascial
layers [3].
4. Treatment
Treatment of mucormycosis combines surgical intervention
and antifungal therapy. Liposomal amphotericin B is the
drug of choice for the therapy of mucormycosis. The in
vitro susceptibility testing for amphotericin B gives a broad
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range of values according to the genus and the species.
With the exception of posaconazole, the azole derivatives
show a limited in vitro activity against Mucorales, and the
echinocandins have a limited activity against these fungi
[14]. Studies of in vitro combination of posaconazole with
amphotericin B showed synergistic eﬀects against hyphae of
some species [15]. In addition, combination therapy with
liposomal amphotericin B plus caspofungin or posaconazole
and posaconazole with colony-stimulating factor has been
successfully used in experimental infections [10, 16–18]. In
humans, combination therapy (liposomal amphotericin B
plus echinocandins or posaconazole with or without iron
chelation) has been used as aggressive antifungal treatment
following surgical resection of the damaged tissue [19–
23]. Patients treated with combination of antifungal drugs
had a better survival outcome than those treated with
amphotericin B alone [20, 21]. A promising therapeutic
approach consists of the use of iron chelation. Although
deferoxamine therapy is associated with a high risk to
develop mucormycosis [2, 3, 5–7, 9–11, 24], newer iron
chelators (deferiprone and deferasirox) have not been associ-
ated with increased risk of mucormycosis and have been used
as therapeutic agents in cases of experimental mucormycosis
[24].
5. Virulence Traits and Pathogenesis
According to Casadevall and Pirofski [25]: “Quantitative and
qualitative measures of virulence vary as a function of host
factors, microbial factors, environmental factors, social factors
and interactions amongst them”. This concept is especially
true if we consider opportunistic microorganisms such
as fungi. Macrophages and neutrophils play the major
role in immune defence against agents of mucormycosis.
Prolonged neutropenia is thus the main risk factor for
developing the disease. Moreover, therapeutic interventions
(i.e., corticosteroid therapy), that cause functional defects
in macrophages and neutrophils, represent additional risk
factors for mucormycosis. Diabetes itself can impair the
function of neutrophils contributing to the severity of
the mucormycosis in patients with ketoacidosis [26]. An
important protective factor against mucormycosis is the low
concentration of free iron in plasma and tissues. Many of
the underlying diseases listed above as predisposing factors
for developing mucormycosis share an iron overload as a
consequence of iron tissue burden, elevated serum transfer-
ring, or increased nontransferrin-bound iron [24]. Iron is
essential for Mucorales either enhancing their growth and
hyphal development in vitro or increasing their pathogenicity
in vivo [27]. Hemodialysis patients under treatment with
deferoxamine (DFO), an iron chelator, are particularly at risk
for mucormycosis, and Boelaert and coworkers [28] reported
a high mortality (89%) in 46 patients who developed severe
mucormycosis during DFO treatment. The same group [27,
29] was able to demonstrate that Mucorales use DFO as a
xeno-siderophore, being capable to detach iron from DFO
in a very eﬃcient manner. More recently, other investigators
confirmed the importance of iron in the pathogenicity of
Mucorales by studying the expression of the FTR1 (high-
aﬃnity iron permease of R. oryzae) gene and its product [30].
The authors were able to demonstrate the eﬀect of gene dis-
ruption and gene silencing on R. oryzae, which was unable to
acquire iron in vitro and showed a reduced virulence in mice.
Consistently, anti-Ftr1p antibodies protected mice from
R. oryzae infection [30]. Angioinvasion with subsequent
infarction of the surrounding tissue is uniformly present
in all cases of severe disseminated mucormycosis [31].
Specific adhesion to endothelial cells and internalization of
the fungus by the endothelial cells are important for the
pathogenic strategy of Mucorales [32]. More recently, Liu
and coworkers [33] demonstrated that a novel host receptor
(the glucose-regulated protein 78 [GPR78]) facilitates the
invasion of human endothelial cells by Rhizopus oryzae. This
study demonstrated that in the presence of high iron and
glucose concentrations, such as in diabetic subjects, there
is a direct relationship between an increased expression of
GPR78 and an increased damage to endothelial cells in
diabetic mice [33]. Involvement of the CNS is common
in invasive mucormycosis, Mucorales are capable to gain
access to the central nervous system (CNS) by local vessels
invasion or direct extension from paranasal sinuses [1–3, 5–
11]. Another possible mechanism, involving a retrograde
extension of the fungi into CNS by means of the nerves, was
hypothesized by Frater and coworkers [31]. By evaluating
the histologic features of 20 patients with invasive disease,
they found a high percentage of perineural invasion. A
further fascinating hypothesis concerning the virulence of
Mucorales, in particular of Rhizopus species—the most
common etiological agents of disseminated mucormycosis—
is a possible involvement of endosymbiotic bacteria in the
pathogenesis of the disease [34]. The authors formulate their
hypothesis on the basis of the ability of Rhizopus species to
live with endosymbiotic toxin-producing bacteria [35] and
of the existing link between emergence of mucormycosis and
the increased drug resistance of Gram-negative bacteria seen
in the recent decades. Later on, both the groups of researchers
demonstrated that endosymbiotic toxin-producing bacteria
were not essential for the pathogenesis of mucormycosis
[36, 37]. Other potential virulence factors of Mucorales
could be proteolytic, lipolytic, and glycosidic enzymes as
well as metabolites like alkaloids or mycotoxins as agro-
clavine. However, their direct involvement in human cases
of mucormycosis has been still to be documented [3].
6. Diagnosis
Histology and culture are still the most important diagnostic
approaches for mucormycosis because of the lacking of
molecular diagnosis methods standardized or commercially
available. Moreover the β-1–3 glucan detection is not useful
in this kind of infection due to the extremely low content
of this molecule in the Mucorales [38, 39]. Timely diagnosis
of invasive mucormycosis is essential due to the rapid
progression of the disease, and because signs and symptoms
of the infection could mimic other invasive fungal infections.
Tissue biopsies are the clinical specimens of choice and
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Figure 1: Aseptate hyphae with wide branching angles and large
diameter from a lung fungus ball suggestive of mucormycosis (GMS
stain 400×).
should be submitted to histopathological and microbiolog-
ical examination. When cultures are performed, it should be
remembered that slicing rather than grinding of the samples
should be adopted, because grinding could result in the
loss of viability due to the coenocytic characteristics of the
mycelium. Microscopic detection of aseptate or pauciseptate
hyphae with a large diameter and wide branching angles
is suggestive of mucormycosis (Figure 1). Histopathological
examination of the infected tissues reveals inflammatory
response, often entirely filled with neutrophils, invasion of
arterial and venous walls (angioinvasion) with subsequent
infarction, and perineural invasion [31].
7. Conclusion
Invasive mucormycosis is an important cause of morbidity
and mortality in patients with impaired immune defence
and severe underlying diseases. In immunocompromised
or debilitated patients, the disease is rapidly progressive,
refractory to antifungal therapy, and often cause of death.
Several characteristics of Mucorales have been involved in the
pathogenesis of the infection as potential virulence factors,
but a trait that can be considered a specific determinant
of virulence has not been defined yet. Angioinvasion, neu-
rotropism, and iron uptake are common characteristics of
Mucorales that trigger diseases in humans. Many open issues
remain to be clarified on the interaction betweenmembers of
the Mucorales order and the host immune response. Diﬀerent
therapeutic approaches, especially the combination therapy,
seem to have a promising impact on the clinical outcome
of this infection. However, the development of the most
severe forms of mucormycosis and the subsequent outcome
is strictly dependent on the eﬃciency of the host immune
system.
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